Good Rx Holdings, Inc. GDRX
We take great care to ensure that the data presented and summarized in this overview for GoodRx Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GDRX
View all-
Francisco Partners Management, LP San Francisco, CA60.1MShares$210 Million44.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.58MShares$30 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN4.82MShares$16.9 Million0.01% of portfolio
-
Lakewood Capital Management, LP New York, NY4.16MShares$14.6 Million1.67% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.6MShares$12.6 Million0.03% of portfolio
-
Silver Lake Group, L.L.C. Menlo Park, CA3.53MShares$12.4 Million0.36% of portfolio
-
Petrus Trust Company, Lta Dallas, TX3.1MShares$10.8 Million1.8% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.5MShares$8.74 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.74MShares$6.08 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.1.67MShares$5.85 Million0.03% of portfolio
Latest Institutional Activity in GDRX
Top Purchases
Top Sells
About GDRX
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
Insider Transactions at GDRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2025
|
Romin Nabiey Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,719
-1.24%
|
$5,157
$3.54 P/Share
|
|
Aug 15
2025
|
Romin Nabiey Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,804
+3.34%
|
-
|
|
Aug 08
2025
|
Romin Nabiey Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,531
-3.27%
|
$13,593
$3.47 P/Share
|
|
Aug 08
2025
|
Romin Nabiey Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,663
+8.36%
|
-
|
|
Jul 08
2025
|
Ian T Clark Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,248
+14.69%
|
$68,992
$4.74 P/Share
|
|
Jul 03
2025
|
Spectrum Equity Vii, L.P. |
SELL
Open market or private sale
|
Indirect |
10,677
-100.0%
|
$42,708
$4.8 P/Share
|
|
Jul 02
2025
|
Spectrum Equity Vii, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
3,989,323
-100.0%
|
-
|
|
Jul 02
2025
|
Spectrum Equity Vii, L.P. |
BUY
Conversion of derivative security
|
Indirect |
4,000,000
+50.0%
|
-
|
|
Jun 08
2025
|
Romin Nabiey Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,449
-1.74%
|
$17,796
$4.08 P/Share
|
|
Jun 08
2025
|
Romin Nabiey Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,433
+4.55%
|
-
|
|
Jun 06
2025
|
Spectrum Equity Vii, L.P. |
SELL
Open market or private sale
|
Indirect |
10,677
-100.0%
|
$42,708
$4.09 P/Share
|
|
Jun 05
2025
|
Spectrum Equity Vii, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
3,989,323
-100.0%
|
-
|
|
Jun 05
2025
|
Spectrum Equity Vii, L.P. |
BUY
Conversion of derivative security
|
Indirect |
4,000,000
+50.0%
|
-
|
|
Jun 03
2025
|
Douglas Joseph Hirsch Director |
BUY
Grant, award, or other acquisition
|
Direct |
57,050
+21.25%
|
-
|
|
Jun 03
2025
|
Agnes Rey Giraud Director |
BUY
Grant, award, or other acquisition
|
Direct |
57,050
+26.2%
|
-
|
|
Jun 03
2025
|
Kelly J. Kennedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
57,050
+33.94%
|
-
|
|
Jun 03
2025
|
Ian T Clark Director |
BUY
Grant, award, or other acquisition
|
Direct |
57,050
+40.76%
|
-
|
|
Jun 03
2025
|
Scott Wagner Director |
BUY
Grant, award, or other acquisition
|
Direct |
57,050
+23.85%
|
-
|
|
Jun 03
2025
|
Ronald E Bruehlman Director |
BUY
Grant, award, or other acquisition
|
Direct |
57,050
+38.97%
|
-
|
|
May 15
2025
|
Romin Nabiey Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,719
-1.43%
|
$6,876
$4.27 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 431K shares |
|---|---|
| Exercise of conversion of derivative security | 635K shares |
| Conversion of derivative security | 32.3M shares |
| Payment of exercise price or tax liability | 264K shares |
|---|---|
| Bona fide gift | 193K shares |
| Sale (or disposition) back to the issuer | 20M shares |
| Other acquisition or disposition | 12M shares |
| Open market or private sale | 32K shares |